{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:58:16Z","timestamp":1760821096963,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"scientific research","award":["16H04713"],"award-info":[{"award-number":["16H04713"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["17ck0106287h0001","16cm0106301h0001","15ck0106132h0002"],"award-info":[{"award-number":["17ck0106287h0001","16cm0106301h0001","15ck0106132h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12185-019-02728-5","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T17:02:56Z","timestamp":1567098176000},"page":"389-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CCR4 is rarely expressed in CCR4-mutated T\/NK-cell lymphomas other than adult T-cell leukemia\/lymphoma"],"prefix":"10.1007","volume":"110","author":[{"given":"Yuma","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Murase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satsuki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Murase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuzo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9916-4862","authenticated-orcid":false,"given":"Hiroshi","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"2728_CR1","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","volume":"99","author":"O Yoshie","year":"2002","unstructured":"Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood. 2002;99:1505\u201311.","journal-title":"Blood"},{"key":"2728_CR2","first-page":"3625","volume":"9","author":"T Ishida","year":"2003","unstructured":"Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9:3625\u201334.","journal-title":"Clin Cancer Res"},{"key":"2728_CR3","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","volume":"16","author":"T Ishii","year":"2010","unstructured":"Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2010;16:1520\u201331.","journal-title":"Clin Cancer Res"},{"key":"2728_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s12185-018-2509-0","volume":"108","author":"J Nakashima","year":"2018","unstructured":"Nakashima J, Imaizumi Y, Taniguchi H, Ando K, Iwanaga M, Itonaga H, et al. Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia\u2013lymphoma. Int J Hematol. 2018;108:516\u201323.","journal-title":"Int J Hematol"},{"key":"2728_CR5","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","volume":"28","author":"K Yamamoto","year":"2010","unstructured":"Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia\u2013lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591\u20138.","journal-title":"J Clin Oncol"},{"key":"2728_CR6","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157\u201363.","journal-title":"J Clin Oncol"},{"key":"2728_CR7","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1084\/jem.20140987","volume":"211","author":"M Nakagawa","year":"2014","unstructured":"Nakagawa M, Schmitz R, Xiao W, Goldman CK, Xu W, Yang Y, et al. Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma. J Exp Med. 2014;211:2497\u2013505.","journal-title":"J Exp Med"},{"key":"2728_CR8","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ng.3415","volume":"47","author":"K Kataoka","year":"2015","unstructured":"Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, et al. Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet. 2015;47:1304\u201315.","journal-title":"Nat Genet"},{"key":"2728_CR9","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","volume":"132","author":"Y Sakamoto","year":"2018","unstructured":"Sakamoto Y, Ishida T, Masaki A, Murase T, Yonekura K, Tashiro Y, et al. CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment. Blood. 2018;132:758\u201361.","journal-title":"Blood"},{"key":"2728_CR10","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","volume":"10","author":"T Ishida","year":"2004","unstructured":"Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10:5494\u2013500.","journal-title":"Clin Cancer Res"},{"key":"2728_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s12185-010-0513-0","volume":"91","author":"N Asano","year":"2010","unstructured":"Asano N, Suzuki R, Ohshima K, Kagami Y, Ishida F, Yoshino T, et al. Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. Int J Hematol. 2010;91:426\u201335.","journal-title":"Int J Hematol"},{"key":"2728_CR12","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/path.4699","volume":"238","author":"N Yoshida","year":"2016","unstructured":"Yoshida N, Miyoshi H, Kato T, Sakata-Yanagimoto M, Niino D, Taniguchi H, et al. CCR4 frameshift mutation identifies a distinct group of adult T cell leukaemia\/lymphoma with poor prognosis. J Pathol. 2016;238:621\u20136.","journal-title":"J Pathol"},{"key":"2728_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol. 2003;4:330\u20136.","journal-title":"Nat Immunol"},{"key":"2728_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.immuni.2005.01.016","volume":"22","author":"JD Fontenot","year":"2005","unstructured":"Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22:329\u201341.","journal-title":"Immunity"},{"key":"2728_CR15","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1084\/jem.194.6.847","volume":"194","author":"A Iellem","year":"2001","unstructured":"Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med. 2001;194:847\u201353.","journal-title":"J Exp Med"},{"key":"2728_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1084\/jem.187.1.129","volume":"187","author":"R Bonecchi","year":"1998","unstructured":"Bonecchi R, Bianchi G, Bordignon PP, D\u2019Ambrosio D, Lang R, Borsatti A, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187:129\u201334.","journal-title":"J Exp Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02728-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02728-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02728-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T23:59:52Z","timestamp":1598572792000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02728-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2728"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02728-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2019,8,29]]},"assertion":[{"value":"26 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yuma Sakamoto, Keiichiro Fujii, Shunji Murase, Satsuki Nakano, Ayako Masaki, Takayuki Murase, and Shigeru Kusumoto have no conflicts of interest. Shinsuke Iida received research funding from Ono, Janssen, Celgene, Bristol-Myers Squibb, Takeda, Novartis, Chugai, Kyowa Hakko Kirin, Sanofi, MSD, Daiichi Sankyo and Gilead, AbbVie, and honoraria from Ono, Janssen, Celgene, Bristol-Myers Squibb, Takeda, Novartis and Daiichi-Sankyo. Atae Utsunomiya received honoraria from Kyowa Hakko Kirin and Celgene. Ryuzo Ueda had a consultancy with Mundipharma, Ono, and Terumo, and received research funding from Kyowa Hakko Kirin, Rikaken, Medical & Biological Laboratories, and Chugai, and honoraria from Chugai, Kyowa Hakko Kirin, and Ono. Takashi Ishida received research funding from Kyowa Hakko Kirin, Bayer, and Celgene, and honoraria from Kyowa Hakko Kirin, and Celgene. Hiroshi Inagaki received research funding from Kyowa Hakko Kirin and honoraria from Kyowa Hakko Kirin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}